- Research Associate III
- Office: 295N
- Phone: 401.874.9472
- Email: firstname.lastname@example.org
- Mailing Address: 7 Greenhouse Road, Kingston, RI 02881
Chuck joined the Department of Pharmacy Practice in July 2013 as a data researcher / analyst. Chuck is working in support several funded initiatives with state agency partners to evaluate and improve medication utilization. He was formerly Research Scientist / Database Researcher with United BioSource Corporation, where he led analyses in support of pharmacoepidemiologic and health outcome studies. Chuck has nearly 20 years of experience as a research consultant, having collaborated with numerous pharmaceutical companies, prominent research organizations and experts. His objective is to grow our portfolio of projects in the area of pharmacoeconomics and managed care pharmacy.
Doctoral student, Pharmacoepidemiology, University of RI
MS, Statistics, University of RI
BS, Math education / statistics, Boston University
Schneider G, Juday T, Wentworth C, Lanes S, Hebden T, Seekins D. Impact of health care payor type on HIV stage of illness at time of initiation of antiretroviral therapy in the USA. AIDS Care, 2013; published online.
Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C, Bate A. An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. Drug Safety, 2013; 36(2): 119-134
Jara M, Wentworth C 3rd, Lanes S. A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD. BMJ Open, 2012; 2(3).
Arellano FM, Arana A, Wentworth C, Vidaurre C, Chipps BE. Prescription patterns for asthma medications in children and adolescents with health care insurance in the United States. Pediatric Allergy Immunology, 2011; 22(5): 469-476.
Xue F, Wentworth C, Ganesh V, Gastanaga V, Stryker S, Cha S, Zhao S. Renal impairment, hemoglobinuria, hemoglobinemia among patients with idiopathic thrombocytopenia purpura. American Journal Hematology, 2011; 86(9): 738-742.
Ambegaonkar BM, Wentworth C, Allen C, Sazonov V. Association between extended-release niacin treatment and glycemic control in patients with type 2 diabetes mellitus: analysis of an administrative-claims database. Metabolism, 2011; 60(7): 1038-1044
Arana A, Wentworth C, Ayuso-Mateos JL, Arellano F. Suicide-related events in patients treated with antiepileptic drugs. New England Journal of Medicine, 2010; 363: 542-551.
Arana A, Wentworth CW, Arellano FM. Validity of the codes of suicidality in the THIN database. Pharmacoepidemiol Drug Safety, 2010;19(12):1316-1317
Arana A, Wentworth C, Fernandez-Vidaurre C, Schlienger RG, Conde E, Arellano F. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. British Journal of Dermatology, 2010; 163(5): 1036-1043.
Alejandro Arana, Sam Allen, Jo¨rg Burkowitz, Valerio Fantoni, Ola Ghatnekar, Marı´a Teresa Rico, Nathalie Vanhaverbeke, Charles E. Wentworth, Max Brosa and Felix M. Arellano. Infliximab Paediatric Crohn’s Disease Educational Plan A European, Cross-Sectional, Multicentre Evaluation. Drug Safety, 2010; 33 (6): 1-13
Foody JM, Sajjan SG, Hu XH, Ramey DR, Neff DR, Tershakovec AM, Tomassini JE, Wentworth C, Tunceli K. Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients. Journal Clinical Lipidol, 2010; 4(2): 126-132
Sazonov V, Beetsch, Phatak H, Wentworth C, Evan M. Association between dylipidemia and vascular events in patients treated with statins: Report from the UK General Practice Research Database. Atherosclerosis, 2009
Arellano FM, Arana A, Wentworth C, Fernandez-Vidaurre C, Schlienger RG, Conde E. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. Journal of Clinical Immunology, 2009; 125(3): 1111-1116.
Chandwani S, Wentworth C, Burke TA, Patterson TF. Utilizatin and dosage patterns of echinocandins for treatment of fungal infections in US hospital practice. Curr Med Re Opin, 2009; 25(2): 385-393
Phatak H, Wentworth C, Sazonov V, Burke T. Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. Atherosclerosis, 2009; 202(1): 225-233
Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Arana A, Rothman KJ. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Pharmacoepidemiology Drug Safety, 2008;17(10):1037
Phatak H, Wentworth C, Burke T. Lipid testing among patients beginning statin therapy in general practice in the United Kingdom. Value Health, 2008 Sep-Oct; 11(5): 933-938
Kamal-Bahl S, Burke T, Watson D, Wentworth C. Dosage, titration, and gaps in treatment with extended release niacin in clinical practice. Current Medical Research and Opinion, 2008; 30 (6): 1819-1823
Thomas A. Burke, Miriam C. Sturkenboom, Pamela A. Ohman-Strickland, Charles E. Wentworth, George G. Rhoads. The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus. Pharmacoepidemiology and Drug Safety. Published Online: 2 Jul 2007
Jara M, Lanes S, Wentworth C, May C, Kesten S. Comparative Safety of Long-Acting Inhaled Bronchodilators. Drug Safety, 2007; 30 (12): 1151-1160
Arellano FM, Wentworth C, Arana A, Fernandez C, Paul C. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. Journal of Investigative Dermatology, 2007; 127: 808-816.
Kamal-Bahl SJ, Burke T, Watson D, Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol, 2007; 99(4): 530-4
Arellano FM, Yood M, Wentworth C, Oliveria S, Rivero E, Verma A, Rothman K. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAID) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiology and Drug Safety 2006; 15: 861-872
Keston S, Jara M, Wentworth C, Lanes S. Pooled Clinical Trial Analysis of Tiotropium Safety. Chest, 2006; 130: 1695-1703
Burke TA, Sturkenboom MC, Lu S, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006; 24: 1193–1200
Zhao SZ, Wentworth C, Burke TA, Makuch RW. Drug Switching Patterns Among Patients With Rheumatoid Arthritis and Osteoarthritis Using COX-2 Specific Inhibitors and Non Specific NSAIDs. Pharmacoepidemiology and Drug Safety 2004, 13(5): 277-287
Rothman KJ, CE Wentworth. Mortality of cystic fibrosis patients receiving tobramycin solution for inhalation. Epidemiology 2003, 14(1): 55-59
Osterhaus, J, C May, T Burke, CE Wentworth. Physician-reported management of edema and destabilized blood pressure in COX-2 specific inhibitor users with OA and treated hypertension. Clinical Therapeutics, 2002; volume 24, number 6 (969-989)
Johnson ES, SF Lanes, CE Wentworth, MH Satterfield, BL Abebe, LW Dicker. A metaregression analysis of the dose-response effect of aspirin on stroke. Archives of Internal Medicine, 1999; 159: 1248-1253
Lanes SF, JE Garrett, CE Wentworth, JM Fitzgerald, JP Karpel. The effect of adding nebulized ipratropium bromide to salbutamol (albuterol) in the treatment of acute asthma: a pooled analysis of three trials. Chest, 1998; 114: 365-372
Lanes SF, LL Lanza, CE Wentworth. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. American Journal of Respiratory and Critical Care Medicine, 1998; 158: 857-861